{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T22:42:57Z","timestamp":1770504177064,"version":"3.49.0"},"reference-count":24,"publisher":"Hindawi Limited","issue":"12","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2100,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1111\/j.1742-1241.2009.02228.x","type":"journal-article","created":{"date-parts":[[2009,10,14]],"date-time":"2009-10-14T16:12:16Z","timestamp":1255536736000},"page":"1762-1784","source":"Crossref","is-referenced-by-count":89,"title":["Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic"],"prefix":"10.1155","volume":"63","author":[{"given":"L.","family":"Citrome","sequence":"first","affiliation":[]}],"member":"98","reference":[{"key":"10.1111\/j.1742-1241.2009.02228.x-BIB1","volume-title":"FDA Approves Saphris to Treat Schizophrenia and Bipolar Disorder","author":"United States Food and Drug Administration"},{"key":"10.1111\/j.1742-1241.2009.02228.x-BIB2","volume-title":"Saphris (Asenapine) Sublingual Tablets US Prescribing Information","author":"Schering-Plough Corporation"},{"key":"10.1111\/j.1742-1241.2009.02228.x-BIB3","volume-title":"Update 4 - Akzo, Pfizer Scrap Asenapine Joint Development","author":"Stevenson"},{"key":"10.1111\/j.1742-1241.2009.02228.x-BIB4","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/0091-3057(90)90298-V","article-title":"Actions of ORG 5222 as a novel psychotropic agent","volume":"35","author":"Costall","year":"1990","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1111\/j.1742-1241.2009.02228.x-BIB5","volume-title":"Saphris (Asenapine) Sublingual Tablets. Briefing Book","author":"United States Food and Drug Administration"},{"key":"10.1111\/j.1742-1241.2009.02228.x-BIB6","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.4088\/JCP.v68n1004","article-title":"Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial","volume":"68","author":"Potkin","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"10.1111\/j.1742-1241.2009.02228.x-BIB7","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/clpt.2009.44","article-title":"Modeling and simulation of the time course of asenapine exposure response and dropout patterns in acute schizophrenia","volume":"86","author":"Friberg","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/j.1742-1241.2009.02228.x-BIB8","first-page":"41","article-title":"Asenapine in the treatment of negative symptoms of schizophrenia: clinical trial design and rationale","volume":"40","author":"Alphs","year":"2007","journal-title":"Psychopharmacol Bull"},{"key":"10.1111\/j.1742-1241.2009.02228.x-BIB9","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s002130050301","article-title":"Central 5-HT2A and D2 dopamine receptor occupancy after sublingual administration of ORG 5222 in healthy men","volume":"131","author":"Andr\u00e9e","year":"1997","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1111\/j.1742-1241.2009.02228.x-BIB10","doi-asserted-by":"crossref","first-page":"781","DOI":"10.2165\/11200860-000000000-00000","article-title":"Asenapine","volume":"23","author":"Weber","year":"2009","journal-title":"CNS Drugs"},{"key":"10.1111\/j.1742-1241.2009.02228.x-BIB11","volume-title":"Saphris (Asenapine) Sublingual Tablets. Briefing Document (Background Package)","author":"Schering-Plough Research Institute"},{"key":"10.1111\/j.1742-1241.2009.02228.x-BIB12","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1097\/SMJ.0b013e3180f63246","article-title":"Show me the evidence: using number needed to treat","volume":"100","author":"Citrome","year":"2007","journal-title":"South Med J"},{"key":"10.1111\/j.1742-1241.2009.02228.x-BIB13","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/j.1600-0447.2008.01194.x","article-title":"Compelling or irrelevant? Using number needed to treat can help decide","volume":"117","author":"Citrome","year":"2008","journal-title":"Acta Psychiatr Scand"},{"key":"10.1111\/j.1742-1241.2009.02228.x-BIB14","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2174\/157488609789006985","article-title":"Quantifying risk: the role of absolute and relative measures in interpreting risk of adverse reactions from product labels of antipsychotic medications","volume":"4","author":"Citrome","year":"2009","journal-title":"Curr Drug Saf"},{"key":"10.1111\/j.1742-1241.2009.02228.x-BIB15","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.biopsych.2005.09.014","article-title":"Size of treatment effects and their importance to clinical research and practice","volume":"59","author":"Kraemer","year":"2006","journal-title":"Biol Psychiatry"},{"issue":"Suppl. 11","key":"10.1111\/j.1742-1241.2009.02228.x-BIB16","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1017\/S1092852900025086","article-title":"Atypical antipsychotics: matching receptor profile to individual patient\u2019s clinical profile","volume":"9","author":"Shayegan","year":"2004","journal-title":"CNS Spectr"},{"key":"10.1111\/j.1742-1241.2009.02228.x-BIB17","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/0269881107082944","article-title":"Asenapine: a novel psychopharmacologic agent with a unique human receptor signature","volume":"23","author":"Shahid","year":"2009","journal-title":"J Psychopharmacol"},{"key":"10.1111\/j.1742-1241.2009.02228.x-BIB18","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/sj.npp.1300027","article-title":"H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs","volume":"28","author":"Kroeze","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1111\/j.1742-1241.2009.02228.x-BIB19","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/00127893-200205000-00004","article-title":"Diagnosis and treatment of neutrally mediated syncope","volume":"8","author":"Kaufmann","year":"2002","journal-title":"Neurologist"},{"key":"10.1111\/j.1742-1241.2009.02228.x-BIB20","volume-title":"NDA Approval Letter","author":"United States Food and Drug Administration"},{"key":"10.1111\/j.1742-1241.2009.02228.x-BIB21","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis","volume":"373","author":"Leucht","year":"2009","journal-title":"Lancet"},{"key":"10.1111\/j.1742-1241.2009.02228.x-BIB22","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1176\/appi.ajp.2008.08030368","article-title":"A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia","volume":"166","author":"Leucht","year":"2009","journal-title":"Am J Psychiatry"},{"key":"10.1111\/j.1742-1241.2009.02228.x-BIB23","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/sj.mp.4002136","article-title":"How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials","volume":"14","author":"Leucht","year":"2009","journal-title":"Mol Psychiatry"},{"key":"10.1111\/j.1742-1241.2009.02228.x-BIB24","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1517\/14656560903061309","article-title":"Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making","volume":"10","author":"Volavka","year":"2009","journal-title":"Expert Opin Pharmacother"}],"container-title":["International Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1742-1241.2009.02228.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1742-1241.2009.02228.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T06:08:47Z","timestamp":1643350127000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1742-1241.2009.02228.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":24,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2009,12]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1742-1241.2009.02228.x","relation":{},"ISSN":["1368-5031","1742-1241"],"issn-type":[{"value":"1368-5031","type":"print"},{"value":"1742-1241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}